Promising combo aims to boost remission in follicular lymphoma
NCT ID NCT05994235
First seen Apr 10, 2026 · Last updated Jun 20, 2026 · Updated 15 times
Summary
This phase II trial is testing a combination of two drugs—tazemetostat pills and mosunetuzumab injections—in 23 people with follicular lymphoma who have not yet received treatment. The goal is to see if the combination is safe and leads to a complete response (disappearance of cancer). Tazemetostat blocks a protein that helps lymphoma grow, while mosunetuzumab helps guide immune cells to attack the cancer. The study uses a newer, under-the-skin form of mosunetuzumab.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Weill Cornell Medicine/NewYork-Presbyterian Hospital
New York, New York, 10065, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
tazemetostat pills and mosunetuzumab injections
What this could lead to
If this combination works well, it could offer a more effective and convenient treatment option for people with newly diagnosed follicular lymphoma, potentially increasing the chance of complete remission.
What could go wrong
This is a small, early-phase trial with only 23 participants, so results may not apply to everyone. The drugs have not been tested together before, and there are risks like cytokine release syndrome and nerve-related side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.